Clinical Trials

Are you an adult planning to get a left ventricular assist device (LVAD) implant to treat heart failure? If so, you may be able to take part in a clinical trial about heart failure. Researchers are testing whether a dietary supplement can improve heart function for people with advanced heart failure. To participate, you must be at least 18 years old and be scheduled for elective LVAD implantation. The study is taking place in Seattle, Washington.

Are you at least 18 years old and have been told by your doctor that you need a procedure called transcatheter aortic valve replacement? This study will test a new device designed specifically for use during a procedure called transcatheter aortic valve replacement. Researchers want to make transcatheter aortic valve replacement safer. To be in the study, you must be at least 18 and need a transcatheter aortic valve replacement. The study will take place in locations in California, Georgia, Massachusetts, New York, Virginia, Washington, and Washington, D.C.

This project will determine the health impact of parenthood on people with cystic fibrosis (CF). The study team will use retrospective data to provide relatively immediate evidence on parenthood's effect on pulmonary health.

The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.

Are you an adult with pulmonary arterial hypertension (PAH) and currently taking vasodilators? This study is testing the efficacy of a new medicine called famotidine for people with PAH. Participants in this study must be between 18 and 80 years old and willing to take famotidine or a placebo for 6 months. This study takes place in Seattle, Washington.

Are you an adult diagnosed with cystic fibrosis who would like to help test web-based educational resources designed to inform and prepare patients to make decisions about lung transplantation? This study will determine if it is feasible for study participants to complete use of an assigned web-based educational program, and evaluate whether providing certain educational resources leaves participants more prepared to make future treatment decisions involving lung transplantation with their health care provider(s). To participate in this study, you must be at least 18 years old. This study takes place in Seattle, Washington.

Are you a woman 18 years old or older who has been diagnosed with LAM? This study is examining whether long-term treatment with medicine called sirolimus can stop lung damage in women who have LAM. This study takes place at multiple locations in the United States.

The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.

This study will leverage state-of-the-art, 24-hour behavior assessment in each trimester of pregnancy and examine associations with adverse pregnancy outcomes to inform guidelines and future interventions designed to improve women's pregnancy and long-term cardiovascular health.

The overall goal of this study is to use state-of-the-art monitors to objectively measure the 24-hour behavioral cycle in each trimester of pregnancy, and to examine associations of these behaviors with hypertensive disorders of pregnancy and other adverse pregnancy outcomes linked with future cardiovascular disease risk.